Sartorius Stedim Biotech Aktie
174,35
EUR
+6,60
EUR
+3,93
%
174,20
EUR
+5,45
EUR
+3,23
%
Werbung
Sartorius Stedim Biotech Aktie Analyse
| 12.01.26 | Sartorius Stedim Biotech Neutral | Goldman Sachs Group Inc. | |
| 09.01.26 | Sartorius Stedim Biotech Sector Perform | RBC Capital Markets | |
| 10.10.25 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 08.07.25 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 06.06.25 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 16.04.25 | Sartorius Stedim Biotech Market-Perform | Bernstein Research | |
| 29.01.25 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 24.01.25 | Sartorius Stedim Biotech Neutral | UBS AG | |
|
Werbung
|
|||
| 22.10.24 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 03.10.24 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 27.06.24 | Sartorius Stedim Biotech Equal Weight | Barclays Capital | |
| 23.04.24 | Sartorius Stedim Biotech Equal Weight | Barclays Capital | |
| 11.08.23 | Sartorius Stedim Biotech Neutral | Credit Suisse Group | |
| 18.04.23 | Sartorius Stedim Biotech Neutral | Credit Suisse Group | |
Werbung
Werbung